Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NVAX | Common Stock | Options Exercise | $14.4K | +521 | +12.83% | $27.60 | 4.58K | Oct 15, 2021 | Direct | F1 |
transaction | NVAX | Common Stock | Options Exercise | $30.5K | +662 | +14.45% | $46.00* | 5.24K | Oct 15, 2021 | Direct | F1 |
transaction | NVAX | Common Stock | Sale | -$201K | -1.18K | -22.56% | $170.00* | 4.06K | Oct 15, 2021 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -521 | -25.22% | $0.00 | 1.55K | Oct 15, 2021 | Common Stock | 521 | $27.60 | Direct | F1, F2 |
transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -662 | -6.67% | $0.00 | 9.27K | Oct 15, 2021 | Common Stock | 662 | $46.00 | Direct | F1, F3 |
Id | Content |
---|---|
F1 | The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
F2 | Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |
F3 | Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |